Pune-based Gennova Biopharmaceuticals secures US$ 13.38 million funding to develop Nipah virus vaccine

Dr Sanjay Singh, CEO of Gennova Biopharmaceuticals, said the firm will do preclinical and phase 1 vaccine tests in India, where multiple Nipah outbreaks have been reported over the past 20 years.

Read more